Waiting for the next wave...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe the shortage on Lannet is due to providing also for Dexcel...
This would be temporary indeed.
Is that good for us or alarming?
That's what I was thinking Mikah started again in 2019 and after...
So MIKAH never paid Sungen for the co development of its drugs?
I have been dreaming?
Last CC:
Elite has co-development products and co-developed products such as the ones we have with SunGen and Mikah, where the partners helped to fund the development, or they brought formulation expertise to diversify our risk and supplement our capital investment.
There is no point going to Nasdaq if you are not sure you will stay there for the long term.
Trading on the Nasdaq costs a lot of money. If we go for a reverse split we need to make sure we stay there
We do not have enough drugs revenue and diversity to do so.
After we get some blockbusters and one NDA it will make sense to do so.
We have to make sure that our valued investors get value for their investment like je332 and the doctors who invested in elite.
Thanks god he stays.
Replace the investors.
Bullshit scenario.
It would take 10 years for Nasrat to recoup his investment. He is too old for that.
He is 61 years old - he needs to sell Elite within the next 4 years max at a huge profit, if not it would be his failure - he would have invested a lot of money earned in previous companies on a flop.
no - nasrat is the man!!!!
P/E ratio
I believe that the P/E ratio is established more around the future of the company than the current state of the company.
If investors see a bright future for the company, the P/E ratio is likely to move up.
In our case, because Elite is keeping its cards so close to the chest there is NO VISIBILITY into the future, plans, pipeline, new products posted on their website.
I would recommend having the list of new ANDA's (with code names and minimal info about them posted on ELite website) so investors/MM's can relate to the POTENTIAL of the company and the future growth.
When we had SequestOX in the pipeline with real potential of making big money, the share price was higher. These days, the maximum visibility that we have is 3 months - when Nasrat tells us "I expect same levels of revenues for next quarter".
Also if you look at Lannett, it does provide some level of information about the revenues by Product family - we need the same type of information in our Q on a quarterly basis.
My 4 cents
I guess you were not there when we had live questions and a guy would ask a question like: So the FDA did not yet approve that drug? and there was a shorts raid upon Nasrat answering NO.
So he made a strategic decision to receive teh questions upfront and answer the ones he feels are valid.
The more I think about it (and I am a long - you know that), I would like more transparency on the drugs where the R&D is funded by Mikah.
If Mikah decides UPFRONT what drug they will fund R&D for, then I am fine.
If the drug fails or if it requires more funding because of trials, then Mikah is good for it too.
If Mikah decides after fact they they will fund the R&D for approved drugs, then it removes the Risk factor from the equation and that is not OK.
In any case, I would like to see an influx of money from Mikah to Elite in the Q...
ALl the ANDA's are using the same protocol as the Sungen ones. Some are 100% ELITE like stated in the last CC:
"Elite is pragmatic about how we add new products. We look at all alternatives, buying products or product rights, in licensing, co-developing products, contract manufacturing or developing products on our own. Elite has co-development products and co-developed products such as the ones we have with SunGen and Mikah, where the partners helped to fund the development, or they brought formulation expertise to diversify our risk and supplement our capital investment.
We currently have products filed under development and co-developed products. We continue to benefit from these projects. The results of the co-developed product for example is Amphetamine IR and ER. We got that with a partnership with SunGen.
In addition, Elite develops its own products. For that activity, Elite will own a 100% of the product, but Elite will also bear a 100% of the risk and the cost."
A good question for the next CC or before is to ask Nasrat to publish AHEAD OF TIME AND NOT UPON APPROVAL what ANDA are 100% Elite versus co-developed - for transparency and to make the investors aware ahead of time.
aaaaaaaaaaaaaagain fake news
true I do not know - but this is generally part of any business contract - Nasrat also mentioned it in the CC
It is not an easy thing to do to cerate a marketing organization and ramp it up.
Nasrat will be able to do this only after bringing a new drug that will surpass the revenue from both Adderall products combined.
Look for my replies :>>>"
Perhaps one of the knowledgeable posters can clarify what the status of allotted quota from the DEA with respect to Lanett and Elite?
>>> Lanett is a different entity than Elite - they have to have their own quota. This will take some time.
Will Lanett need to apply for a separate quota if they launch?
>>> see above
Also interested if Lanett sells its ANDA of Adderall, will the pharmacies substitute the Elite version?
>>> As long as the current agreement is on, Lanett cannot undermine Elite.
>>> There is always a non-compete clause. Nasrat is a lawyer.
Since Lanett was selling the Elite version, could they undercut the Elite price if and when they launch?
>> They can do that only after the agreement is void. Lanett is bleeding cash - they have to make a strategic decision of stopping the revenue from Elite Adderall vs starting with Nothing and ramp up - I believe this is why they asked for a 2 years agreement - to prepare an offensive in 2 years from the agreement signature.
Not sure about that - Mikah is 1 guy and a router type of company - it is a shell company with no employees. Much easier to manage than a DEA focused pharma company with plenty of employees and risks and FDA on your back and partners etc...
He is taking a HUGE risk - and he would not invest in Elite if he was not 100% sure it would explode one day and make him whole for all his investment and work.
I am not N2K - but I think that as long as we are paying Mikah vs Sungen the same price, and any other partner, I am fine - it helps Elite going back to Nasdaq, and to improve teh balance sheet.
Trying to be pragmatic here - money does not smell - anything that can help ME retire better is good as long as it is legal.
I think the last cc gave us more info than any other cc before.
But it will be a race. The Lannett situation is scary. But the new products are promising.
Glta
It was a few years ago. Vermillion got approved for a pancreatic cancer drug. It went up from 5 cents to $26 in 5 days.
We just need a regular NDA or 4 good generics and you will see this puppy at $1.
The move from Lannett to Internal marketing may impact our revenues - this should happen only after we strengthen the revenue stream from other products.
That makes me so sad...
I want to cry...
Quote:
-------------------------------------------------------------
The antibiotic is dead !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
------------------------------------------------------------
I will as I see a Huge potential upside.
I do not know another CEO who is so transparent with teh activities of his company.
Risks, issues, plans, pipeline, revenue, growth, partnerships, etc...
The Show Started !!!!
Put that in a nice question to Dianne or send her an email with a suggestion
The CEO cannot pump the stock - he reports on what needs to be reported - he is doing his job - the investors are not.
He delivers - we buy
I do not get all this negativity - we had the best quarter ever
We do not need much to explode - talk of a new product, a partnership with a big name, move to Nasdaq...
I wonder if the lower spending on R&d is due to Mikah participation in R&D spending.
Too late to ask the question.
I hope Nasrat provides more visibility into the partnerships and Business development tomorrow.
This is the only thing that will get us above 10 cents.
At the end of the quarter
Investors are letting the company down - the CEO is delivering big time.
No mention of Dexcel deal - it must have happened after the end of the quarter.
Working capital $ 11,596,810
9 million - omg - this is soooo good... Thank you NASRAT for being a great CEO !!!
Remember we have until 7 PM to add to our questions for specific questions about the quarterly results
Around 4:30 PM
he is in a worse shape than most of us in that aspect
Questions for Nasrat:
1) Can you provide the reason for just creating a SEC filing for the Dexcel partnership announcement and not blasting the existing news channels for stocks?
2) Was the Adderall XR newly seen at Walgreens by some investors purchased by Walgreens from Lannett Elite's Adderall?
3) Was the Adderall XR newly seen at Walgreens by some investors part of a recent win by Lannett at Walgreens (after the last teleconference?)
4) In the last teleconference, Pfizer was mentioned 5 times, is there any news related to a potential deal with Pfizer?
5) Do you still see Elite going to Nasdaq in Calendar 2022? (next 10 months)
6) Can you please provide an update to the status of the ANDA's that are supposed to be filed in 2022?
7) What happened to Sungen and the response letter they needed to send to the FDA? Was Elite able to convince Sungen to send it with a good response?
8) Did you try to pay Sungen to finish the job on this ANDA?
9) What is the function of the Florida office?
10) Did Elite suffer from API's provisioning in the last quarter?
11) With the dust settling on the opioid lawsuits, what are the plans for sequestox and ADT OxyContin? Aren’t they just pending approval with the FDA?
bullshit - this is a fortress and has always been...